BurnsAdler Pharmaceuticals, Inc. Partners With Sigma-Tau Finanziaria S.p.A.

Charlotte, North Carolina (February 18, 2005) - BurnsAdler Pharmaceuticals, Inc. announced today that they have partnered with Sigma-Tau S.p.A. for the promotion and distribution of Natulan® (procarbazine) in Latin America and the Caribbean. Natulan® is indicated for use in combination with other anticancer drugs for the treatment of Stage III and IV Hodgkin's disease as part of the MOPP (nitrogen mustard, vincristine, procarbazine, prednisone) treatment regimen. Natulan® was marketed globally by Roche before being acquired by Sigma-Tau.